Margin Execution Drives Better Performance in Quarter and Higher Guidance for Fiscal 2024 Q2 revenue of $5.0 billion increased 4.6% as reported, 4.7% currency-neutral and 5.7% organic Q2 GAAP and...
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $0.95 per common...
By Maureen Mazurek, Chief Sustainability and EHS Officer Climate change is considered one of the greatest threats to human health1. From water scarcity and contamination to reduction in crop...
Discover the new BD. We create medical technology, devices and laboratory equipment for scores of different needs across the healthcare continuum. But we serve all of them with one single and relentless human purpose: advancing the world of health. This is how we make a difference in human health across generations. This is our work and this is our passion.
The BD Innovation and Engagement Center in Eysins Switzerland offers visiting healthcare professionals a collaborative and immersive environment to grasp the full scope of BD solutions to healthcare challenges across the care continuum.
